EU secures additional 100 million doses of Pfizer-BioNTech vaccine for 2021 delivery
Extra supply will bring total number of doses scheduled to be shipped to EU this year to 600 million
The European Union has secured another 100 million doses of the Pfizer-BioNTech COVID-19 vaccine, Comirnaty, for delivery in 2021 after activating a clause in an existing supply contract, the two companies said Monday.
The European Commission’s decision to exercise an option in the advance purchase agreement signed in February brings the total number of doses of the vaccine to be delivered to the 27 EU member states this year to 600 million.
“We now intend to deliver a total of 600 million doses to the EU this year, which covers two thirds of the EU population and represents the largest cumulative supply agreement for Comirnaty that we have agreed to date globally,” said Sean Marett, Chief Business and Chief Commercial Officer of BioNTech.
Pfizer CEO, Albert Bourla, said to date the company had met all of it supply commitments to the EC and planned to deliver 250 million doses to the EU in Q2, “a four-fold increase on Q1’s agreed quantity.”
Back in January, shipments of the vaccine to the bloc were affected by what Pfizer and BioNTech said were changes to the manufacturing processes designed to increase production capacity, but at the time the companies insisted the bottlenecks were only temporary.
The EU has been looking to offset the impact of delays to Johnson & Johnson’s single-shot vaccine, after US regulators review links to rare cases of blood clotting, as well as several member states’ decisions to restrict usage of AstraZeneca’s vaccine.
Last week, the Danish Health Authority removed the AstraZeneca shot entirely from its inoculation programme, saying that based on scientific findings, it had determined there was a real risk of severe side effects with using it.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance